Pharma R&D Cuts Impairing U.S. Competitive Standing
Published: Jan 06, 2014
A recent article in the New England Journal of Medicine (NEJM) should send warning signals to all interested in the state of the biopharmaceutical R&D in the U.S. The article, “Asia’s Ascent – Global Trends in Biomedical R&D Expenditures”, analyzes global biomedical R&D spending for the period between 2007 and 2012. While the article focuses on the relative rise in spending by Japan, China and India, the eye-opening data for me are the numbers from the U.S. The authors point out that the U.S. share of this global spend has fallen from 51.2% in 2007 to 45.4% in 2012. Europe’s investment was essentially unchanged and Asia’s increased from 18.1% to 23.8%. Further digging into the numbers revealed the following.
Hey, check out all the research scientist jobs. Post your resume today!